Invitrogen opens Australian cGMP manufacturing facility

Thursday, 25 August, 2005


Invitrogen has opened a AU$3.4 million cGMP bioproduction facility focused on the development of safe and consistent bovine sera products and reagents used in basic research and the production of vaccines and biotherapeutic drugs for world markets.

cGMP refers to good manufacturing practices required in the design and operation of the facility, processes and quality systems in order to serve global pharmaceutical companies. Invitrogen's site also features new process technology and automation optimised for the standards expected by biopharmaceutical customers.

Australia and New Zealand are among the few countries regarded as being BSE free, as well as having a lower incidence of other viral diseases prevalent in other countries. As a result, global pharmaceutical companies are seeking secure supply of locally produced biotechnology products.

This reputation is important as it encourages global biopharmaceutical customers to source product from this part of the world. It is a global advantage that may encourage Invitrogen to continue to review opportunities to expand its operations in Australia.

Related News

Applications now open for Scopus Researcher Awards

The Scopus Researcher Awards recognise outstanding researchers in Australia and New Zealand who...

AdAlta appoints new CEO, secures licensing deal

The Melbourne drug development company has announced Dr Tim Oldham as its new CEO and signed a...

2019 Nobel Prize winners announced

The 2019 Nobel Prizes acknowledge scientists whose discoveries have opened up possibilities for...


  • All content Copyright © 2019 Westwick-Farrow Pty Ltd